



# The Richard Doll Seminars in Public Health & Epidemiology

## Dr Paul Ridker *Harvard Medical School*

\*\*\*\*\*

“Inflammation and Atherothrombosis:  
Where have we been? Where are  
we going?”

\*\*\*\*\*

**Tuesday 19<sup>th</sup> Feb 2013**  
**1-2 pm**

**Lecture Theatre, Richard Doll Bldg, Old Road Campus**

<http://www.ceu.ox.ac.uk/seminars>


Follow us  [@rdseminars](https://twitter.com/rdseminars)

All welcome



### Dr Paul Ridker

Eugene Braunwald Professor of Medicine,  
Harvard Medical School



Dr. Paul Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women's Hospital in Boston which focuses on the molecular and genetic epidemiology of cardiovascular diseases and on novel strategies for cardiovascular disease detection and prevention.

Dr. Ridker's primary research brings together classical tools of large-scale, population-based epidemiology with emerging genetic and molecular techniques. Particular areas of interest involve epidemiologic studies of thrombosis and inflammation, with a focus on "predictive medicine", early diagnosis, and the underlying causes and prevention of acute coronary syndromes. He has been the PI or Study Chairman of several multi-national trials including PREVENT, PRINCE, val-MARC, LANCET and the JUPITER trial, evaluating the use of statin therapy among 18 000 apparently healthy individuals with low levels of LDL-C and elevated levels of CRP. He is also PI of the Women's Genome Health Study (WGHS) and of the JUPITER-GWAS, two large-scale genome wide association studies with full genomic data on more than 40 000 individuals. Best known for his work on the role of inflammatory biomarkers in cardiovascular disease and diabetes, Dr. Ridker is currently the PI of two new multinational clinical trials - the NIH funded Cardiovascular Inflammation Reduction Trial (CIRT) and the industry funded Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) - both designed to directly test the inflammatory hypothesis of atherothrombosis.

Dr. Ridker has been the recipient of Clinician Scientist and Established Investigator Awards from the American Heart Association, a Doris Duke Distinguished Scientist Award, and has served as a Reynolds Foundation Investigator. The recipient of several honorary medical degrees, Dr. Ridker was honored by Time Magazine as one of America's Ten Best Researchers in Science and Medicine in 2001 and as one of the "Time 100" in 2004.